Lung drug faceoff could have limited upside

Share this article:

Talk of a possible head-to-head comparison between Actelion's pulmonary arterial hypertension drug Opsumit and Gilead's Letairis caused enough of a stir that investors punished Actelion's stock Tuesday. Bloomberg reports the talk triggered a 3.1% drop in Actelion's share price, despite the very theoretical nature of the clinical trial.

Bloomberg notes that a trial has varied risks: a Gilead sweep would be bad news for Actelion, which staked its financial independence on Opsumit's potential, whereas an Actelion win would maybe put a minor dent in a business that accounts for less than 5% of Gilead's sales. Bloomberg also notes that any Gilead advantage would be short lived, because the Letairis patent expires in four years.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.

India's Marck gets FDA Warning Letter

Inspectors of Marck Biosciences found an array of problems during a October-November 2013 inspection, including mold near a sterile area that was so bad "the room had 'partially caved in.'"

DOJ closes Brilinta investigation

AstraZeneca announced the end of the investigation Tuesday.